Novel approaches to detect serum biomarkers for clinical response to interferon-beta treatment in multiple sclerosis.
Interferon beta (IFNbeta) is the most common immunomodulatory treatment for relapsing-remitting multiple sclerosis (RRMS). However, some patients fail to respond to treatment. In this study, we identified putative clinical response markers in the serum and plasma of people with multiple sclerosis (MS) treated with IFNbeta. In a discovery-driven approach, we use 2D-difference gel electrophoresis (DIGE) to identify putative clinical response markers and apply power calculations to identify the sample size required to further validate those markers. In the process we have optimized a DIGE protocol for plasma to obtain cost effective and high resolution gels for effective spot comparison. APOA1, A2M, and FIBB were identified as putative clinical response markers. Power calculations showed that the current DIGE experiment requires a minimum of 10 samples from each group to be confident of 1.5 fold difference at the p<0.05 significance level. In a complementary targeted approach, Cytometric Beadarray (CBA) analysis showed no significant difference in the serum concentration of IL-6, IL-8, MIG, Eotaxin, IP-10, MCP-1, and MIP-1alpha, between clinical responders and non-responders, despite the association of these proteins with IFNbeta treatment in MS.
Gandhi
Kaushal S
KS
Westmead Millennium Institute, University of Sydney, Sydney, Australia.
McKay
Fiona C
FC
Diefenbach
Eve
E
Crossett
Ben
B
Schibeci
Stephen D
SD
Heard
Robert N
RN
Stewart
Graeme J
GJ
Booth
David R
DR
Arthur
Jonathan W
JW
D000328:Adult; D015415:Biomarkers / Q000097:blood; D054413:Chemokine CCL11 / Q000097:blood; D003710:Demography; D015180:Electrophoresis, Gel, Two-Dimensional / Q000379:methods*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D016899:Interferon-beta / Q000627:therapeutic use*; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000097:blood* / Q000188:drug therapy*; D018401:Sample Size; D016896:Treatment Outcome
D015415:Biomarkers; C515456:CCL11 protein, human; D054413:Chemokine CCL11; D015850:Interleukin-6; D016899:Interferon-beta
J Proteome Res. 2005 Sep-Oct;4(5):1867-71
16212444
Acta Neurol Scand. 2003 Jul;108(1):16-21
12807388
J Neuroimmunol. 2002 May;126(1-2):205-12
12020972
Drugs. 2003;63(15):1525-33
12887260
J Mol Neurosci. 2007;32(3):169-78
17873362
Expert Rev Proteomics. 2010 Feb;7(1):29-38
20121474
J Proteome Res. 2005 May-Jun;4(3):809-19
15952727
Neurol Sci. 2001 Apr;22(2):201-3
11603627
Eur J Neurol. 2005 Aug;12(8):588-601
16053466
Neurology. 1999 Nov 10;53(8):1692-7
10563614
Trends Pharmacol Sci. 2006 Jan;27(1):48-55
16310865
J Proteome Res. 2007 Jul;6(7):2884-7
17550277
J Neuroimmunol. 2001 Jan 1;112(1-2):174-80
11108946
J Neurol Sci. 2002 May 15;197(1-2):1-8
11997060
J Neuroimmunol. 2002 Feb;123(1-2):170-9
11880161
J Lipid Res. 1999 Feb;40(2):345-53
9925665
Cytokine. 2006 Oct;36(1-2):69-74
17161613
Proteomics. 2008 Dec;8(23-24):4886-97
19003860
Folia Neuropathol. 2004;42(1):15-8
15119740
Blood. 2001 Apr 15;97(8):2381-9
11290601
J Neuroimmunol. 2004 Oct;155(1-2):161-71
15342208
Mult Scler. 2004 Oct;10(5):507-10
15471365
Clin Chim Acta. 2005 Aug;358(1-2):119-30
15907825
Ann Neurol. 2001 Jul;50(1):121-7
11456302
Cytokine. 2000 Jun;12(6):682-7
10843745
J Neuroimmunol. 2001 Apr 2;115(1-2):161-7
11282166
Neurosci Lett. 2009 Mar 13;452(2):214-7
19383442
Ann Neurol. 2006 Feb;59(2):237-47
16437581
Virchows Arch. 2000 Nov;437(5):521-7
11147173
Proteomics. 2003 Jan;3(1):36-44
12548632
Lancet. 2003 Jun 14;361(9374):2036-43
12814715
Biochim Biophys Acta. 2007 Sep;1774(9):1173-83
17698427
Mult Scler. 2004 Jun;10(3):245-60
15222687
Neurology. 2003 Jul 22;61(2):184-9
12874396
Proteomics. 2004 Jul;4(7):2117-24
15221773
Nat Rev Neurosci. 2001 Jul;2(7):502-11
11433375
J Neurol Sci. 2006 Sep 25;247(2):202-7
16784758
J Cereb Blood Flow Metab. 2003 Sep;23(9):1060-9
12973022
Cell Mol Neurobiol. 2009 Mar;29(2):203-10
18807170
Ann Neurol. 1996 Mar;39(3):285-94
8602746
Immunol Today. 1999 Nov;20(11):500-4
10529777
Proteomics. 2005 Dec;5(18):4713-8
16281180
Clin Chem Lab Med. 2000 Mar;38(3):209-13
10905756
Biochim Biophys Acta. 2004 Nov 5;1690(3):203-7
15511627
J Cell Mol Med. 2009 Aug;13(8A):1586-603
19602050
Lancet. 2003 Oct 11;362(9391):1184-91
14568740
Neurology. 2004 Nov 23;63(10):1779-87
15557490
J Neuroimmunol. 2004 Nov;156(1-2):195-203
15465611
Respir Res. 2001;2(3):150-6
11686879
Electrophoresis. 2001 Jun;22(10):2066-74
11465507
Clin Immunol. 2009 Feb;130(2):145-50
18945642
Cytokine. 2001 Jun 7;14(5):272-82
11444907
Curr Drug Targets Inflamm Allergy. 2004 Sep;3(3):279-90
15379596
Clin Neurol Neurosurg. 2006 Feb;108(2):124-8
16412833